Abstract: The present disclosure provides, inter alia, Compounds of Formula (I) or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.

Abstract: The present disclosure provides, inter alia, Compounds of Formula (I) or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.

Abstract: Systems and methods are described herein for disambiguating a voice search query by determining whether the user made a gesture while speaking a quotation from a content item and whether the user mimicked or approximated a gesture made by a character in the content item when the character spoke the words quoted by the user. If so, a search result comprising an identifier of the content item is generated. A search result representing the content item from which the quotation comes may be ranked highest among other search results returned and therefore presented first in a list of search results. If the user did not mimic or approximate a gesture made by a character in the content item when the quotation is spoken in the content item, then a search result may not be generated for the content item or may be ranked lowest among other search results.

Abstract: The present disclosure is drawn to the combination therapy of a C—C Chemokine Receptor 4 (CCR4) antagonist and one or more immune checkpoint inhibitors in the treatment of cancer.

Abstract: The present disclosure provides, inter alia, methods of treating generalized pustular psoriasis (GPP) by administering an effective amount of a Chemokine Receptor 6 (CCR6) antagonist and/or a C-X-C motif chemokine receptor 2 (CXCR2) antagonist. Also provided herein are methods of modulating dysregulated IL-36 signaling in a subject in need thereof and methods of reducing neutrophil, inflammatory dendritic cell (iDC), and/or CD4 T cell accumulation in a subject in need thereof, said methods, include dministering an effective amount of a Chemokine Receptor 6 (CCR6) antagonist and/or a C-X-C motif chemokine receptor 2 (CXCR2) antagonist.

Abstract: The current disclosure relates to a chemical-free composition that increases the nutritive value of crops, by increasing vitamin levels in the crop produce. The composition disclosed in the current invention also increases crop yield. The composition does not contain any chemicals and can increase vitamin levels in the crop produce by non-transgenic means, which can help to alleviate deficiency diseases due to malnutrition in an inexpensive and sustainable manner.

Abstract: The present invention relates to process for the preparation of 2-(3,5-dichlorophenyl)-1,3- benzoxazole-6-carboxylic acid of formula (I), its pharmaceutically acceptable salts and polymorphs thereof which are used in the treatment of cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis.

Abstract: The present disclosure provides, inter alia, Compounds of Formula (I) or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.

Abstract: Aniline compounds are provided which bind to CCR(4) and are useful for the treatment of diseases such as allergic diseases, autoimmune diseases, graft rejection and cancer.

Abstract: Provided herein are compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. Moreover, provided herein are methods of making or manufacturing compounds disclosed herein, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or Co-crystals and prodrugs thereof.

Abstract: Compounds are provided that are modulators of the CCR2 receptor. The compounds have the general formula (Ia1?): and are useful in pharmaceutical compositions, methods or the treatment of diseases and disorders involving the pathologic activation of CCR2 receptors.

Abstract: Systems and methods are described for extended reality environment interaction. An extended reality environment including an object is generated for display, and a first sensor is used to detect that a gaze has shifted from a first portion of the extended reality environment to a second portion of the extended reality environment, where the object is excluded from the first portion of the extended reality environment and included in the second portion of the extended reality environment. An indicator of the shift in the gaze is generated for display within the extended reality environment in response to detecting the gaze shift, and a voice command is detected by a second sensor while the indicator is in a vicinity of the object. In response to detecting the voice command, an action corresponding to the voice command may be executed.

Abstract: Systems and methods are described for extended reality environment interaction. An extended reality environment including an object is generated for display, and a sensor is used to detect a gaze directed to a first portion of the extended reality environment, where the object is included in the first portion of the extended reality environment. Opacity-based indicators are generated for display in the vicinity of the first portion of the extended reality environment, and a boundary of the object is identified. Based on the identified boundary of the object, an opacity of the at least one of the opacity-based indicators is varied.

Abstract: The Present Invention relates to process for the preparation of 7-{4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy}quinolin-2(1H)-one represented by the following structural formula-1.

Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1a, R1b, R1c, R1d, R2a, R2b, R3, R3a, R4, R6, R7, R8, A, Z, X1 and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Abstract: Compounds are provided to modulate the C5a receptor. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Abstract: Automated methods and systems for generating Grok expressions for extraction of metric data from any type of log message are described. Method and systems include construction of a directed graph from Grok patterns. A sample log message is selected from log messages that record metrics values of a desired metric. The directed graph is used to construct a Grok expression from the sample log message. The Grok expression is then used to parse log messages that are of the same type or format as the sample log message to extract the desired metric data from the log messages. The metric may in turn be used to troubleshoot problems anchor identifying potential root causes of problems in a data center or other type of distributed computing system.

Abstract: Systems and methods are described herein for disambiguating a voice search query by determining whether the user made a gesture while speaking a quotation from a content item and whether the user mimicked or approximated a gesture made by a character in the content item when the character spoke the words quoted by the user. If so, a search result comprising an identifier of the content item is generated. A search result representing the content item from which the quotation comes may be ranked highest among other search results returned and therefore presented first in a list of search results. If the user did not mimic or approximate a gesture made by a character in the content item when the quotation is spoken in the content item, then a search result may not be generated for the content item or may be ranked lowest among other search results.

Abstract: The present disclosure provides, inter alia, methods of treating generalized pustular psoriasis (GPP) by administering an effective amount of a Chemokine Receptor 6 (CCR6) antagonist and/or a C—X—C motif chemokine receptor 2 (CXCR2) antagonist. Also provided herein are methods of modulating dysregulated IL-36 signaling in a subject in need thereof and methods of reducing neutrophil, inflammatory dendritic cell (iDC), and/or CD4 T cell accumulation in a subject in need thereof, said methods, include administering an effective amount of a Chemokine Receptor 6 (CCR6) antagonist and/or a C—X—C motif chemokine receptor 2 (CXCR2) antagonist.

Abstract: The present invention relates to solid state forms of 5-chloro-6-[(2-iminopyrrolidin-1-yl)methyl]pyrimidine-2,4-(1H,3H)-dione hydrochloride compound of formula-1a and their processes for the preparation thereof and an improved process for the preparation of 5-chloro-6-[(2-iminopyrrolidin-1-yl)methyl]pyrimidine-2,4-(1H,3H)-dione hydrochloride. The present inventors also provides an amorphous polymorph of the combination drug consisting of 2?-deoxy-5-(trifluoromethyl) uridine and 5-chloro-6-[(2-iminopyrrolidin-1-yl)methyl]pyrimidine-2,4-(1H,3H)-dione monohydrochloride and its process for the preparation.